ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

AGL Angle Plc

14.00
-0.25 (-1.75%)
24 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.25 -1.75% 14.00 556,436 12:15:17
Bid Price Offer Price High Price Low Price Open Price
13.50 14.50 14.25 13.75 14.25
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Business Services, Nec 1.04M -21.69M -0.0832 -1.68 36.48M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:00:28 O 3,908 13.9956 GBX

Angle (AGL) Latest News

Angle (AGL) Discussions and Chat

Angle (AGL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2024-06-24 15:00:2914.003,908546.95O
2024-06-24 14:57:3013.778,0001,101.60O
2024-06-24 14:57:0214.0042559.48O
2024-06-24 14:49:3113.7910,0001,378.50O
2024-06-24 14:28:4813.795,000689.25O

Angle (AGL) Top Chat Posts

Top Posts
Posted at 24/6/2024 09:20 by Angle Daily Update
Angle Plc is listed in the Business Services, Nec sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 14.25p.
Angle currently has 260,580,547 shares in issue. The market capitalisation of Angle is £36,481,277.
Angle has a price to earnings ratio (PE ratio) of -1.68.
This morning AGL shares opened at 14.25p
Posted at 18/6/2024 14:26 by kryptonsnake
The share price isn't falling fast enough so all the idiots are turning up today

Ignore the noise. The share price will recover and then some

It's just a matter of time before more contracts are signed


sent from my iPhone
Posted at 07/6/2024 08:28 by ohwhatfun
Amt

Re your post below

A bit disappointing after they stated in November " Cash runway extended into Q2 2025 "
Seems like a huge miscalculation or am I being unfair.
Anyway dilution not a disaster and if the are burning say 2m per month should get us through to the end of the year by which time maybe there will have been further breakthroughs to give a decent valuation before the next cash call.


That was the point raised pre fund raise.

They reported an extended cash runway from the end of 2024, first to Q1 25 then ‘into’ Q2.

Logically that was based on Canada savings and revenue hit.

The point being and stated pre raise, that if revenue is not being hit, that drags it back to the end of 2024, fund raise imminent.

Results were delayed beyond typical report times which is a standard bad news warning on AIM stocks for the majority of the time.

I wanted to see £20m at whatever price to remove the cash issue for a year.

All they have done is put a sticky plaster on it in a hope to get contracts/revenue to meet the full year forecast.

The chances of that are likely slim, even for contracts being discussed, one minor contract change can add 3 months to the process, such is the nature of legal bureaucracy.

In that 40% stated some is contracted, not delivered as yet, and may also see delays.

So some (including me) are of the opinion that getting near an extra £4m of sales accounted for this year is a tall order.

If they don’t hit it, they will be forced to release an RNS.

We won’t have to wait 6 months. They will know at interims time which is due by 30th September.

If the cautious are right, then another raise will be needed in quick time on the back of missed revenue and a lower share price.

Gamble made by AGL and the odds of hitting revenue, for those sober heads, is a long shot.

Time will tell, and not that long to wait, just a few months.
Posted at 05/6/2024 07:49 by miavoce
Usual behaviour is that the share price will drop to the offer price as soon as the market opens. This is certainly what I am expecting. If this occurs there will be no forward short selling as that only occurs before the share price has dropped to the offer price.
Posted at 23/5/2024 07:21 by adw198
Placing coming here soon as the cash is running low. Some decent news on deals hoping to lift the share price prior to it but it'doesnt seem to be working and the share price falling back quickly. Depending when it comes likely to be another painful one for shareholders.

A shame as they seem to be getting there just not quite fast enough and that might cost pis here as the market is awful to raise in. Those that have left it late to raise money have been hammered, see Gdr sce, Polx of how tough it might get here.

A shame as I think this out of most of them has a good product and future but not before one mo

———;—


And before you start giving me the thumbs down just reflect they aren’t my words but infact what the rat bones698 was saying on another share yday. He’s obviously short there so that kind of analysis is fine for him to make. What a lair and a hypocrite - don’t fall for it.
Posted at 22/5/2024 21:44 by pj84
There is no doubt in my mind that Angle’s future is very bright, and we are finally approaching the tipping point to commercialisation, which we all expected earlier following the successful FDA approval, but Angle could in the next year or two see revenues start to scale up meaningfully.

As we all know, the actions that Angle announced to reduce non-critical spending, increased the projected cash runway into Qtr 2 25 (1 Apr to 30 Jun 25) which had initially given me comfort there was time for more traction to build, which could improve the share price before any need to raise funds arose.

The apparent delay in even announcing when the year end results will be released has made me more uneasy. On the positive side, it could be because Angle believe they are close to being able to announce something that will have a very positive effect on the share price.

If not, my concern, is that when they announce the results, they will need the auditors to agree that the Accounts can be prepared on a going concern basis which means the auditors are satisfied that Angle has sufficient funds for the 12 months from the date of the audit report which would now mean late May or June 25.

Unless the projected cash runway has since improved, the cash is at best only going to last for just 12 months if the projections were for cash to the later part of Qtr 2. If it was the beginning of Qtr 2, the cash won’t now last for 12 months and even a small change reducing the cash runway could mean they can’t now meet the 12 months.

I don’t know if the delay is positive or negative but the risk of holding now is too great but I expect to return once the situation is clear.
Posted at 12/5/2024 23:19 by liberatingsteptoe
today's DTel Questor: I can think of one Co they might be interested in...... Absolutely no information but it does make one think...... Just hope that things here progress for a while yet and that LTH get their just rewards.


Remember Abcam? The Cambridge-based biotech was a darling of the Aim market until it decided in late-2022 to abandon London in favour of a listing on the US exchange Nasdaq.

The move – Abcam had made Aim its home since 2005 and was one of its biggest companies – was seen at the time as a blow to the Government’s efforts to champion the UK’s most innovative companies.

It was also an indication that the entire London listings market was in decline with many companies since being bought out by predators and seeking higher valuations overseas.

Abcam now has a new owner. Since late last year, the company has been part of Danaher Corporation, the New York-listed life sciences and diagnostics giant.

Danaher paid $5.7bn (£4.6bn) in cash for Abcam, which makes and sells products, including proteins and reagents, used in medical research. It has added the business to its already extensive array of medical products and services, which range from cell production and new drugs discovery to the instruments used in clinical testing.

In its former guise, Abcam had a devoted following among individual UK shareholders. Danaher has a fanbase of its own too: the world’s best fund managers.

Nine of them hold the stock, and each one is among the top 3pc of the 10,000 equity fund managers tracked by financial publisher Citywire. This smart-money backing has led to Danaher being AAA rated by Citywire Elite Companies, which rates companies based on their popularity with the world’s best-performing fund managers.

Danaher share price
Line chart with 1274 data points.
$ per share
View as data table, Danaher share price
The chart has 1 X axis displaying Time. Data ranges from 2019-04-22 00:00:00 to 2024-05-10 00:00:00.
The chart has 1 Y axis displaying $. Data ranges from 107.5989 to 294.6626.
$
2020
2021
2022
2023
2024
50
100
150
200
250
300
SOURCE: BLOOMBERG
Danaher share price
$ per share

End of interactive chart.
While Abcam is not transformational for Danaher – it represents just 2.5pc of overall revenue – top fund manager Neal Kaufman, who holds Danaher shares in the Baron Health Care Fund, says the deal underlines a key attribute: “This acquisition is reflective of Danaher’s thoughtful approach to acquisitions, through which the company has been able to add best-in-class assets in attractive end markets like bioprocessing and proteomics [the study of sets of proteins].”

Management, which has acquired hundreds of businesses since Danaher was created in 1984, is aiming to grow Abcam’s revenues by the high-single-digit percentages over the long term. This is in line with the wider group’s core growth target. It’s an impressive aim for a company of its scale which last year reported revenues just shy of $24bn.

Danaher’s management team is also happy to reshape the group’s portfolio of businesses with disposals.

Last year, for example, it spun off its environmental services arm Veralto to create a separately listed business now worth $24bn. It did the same with its $3.5bn dental operation, Envista, in 2019. In both cases, Danaher’s shareholders benefited, and it would be no surprise to see the company do something similar again.


There is plenty enticing Kaufman and the other leading fund managers backing the company beyond its savvy deals. Among these attractions is Danaher’s wide spread of products, high degree of recurring revenues and those punchy core growth targets already mentioned.

Across the company’s three business lines – of biotechnology, life sciences and diagnostics – around 80pc of revenue is recurring. This provides a striking degree of certainty in a sector where earnings can be volatile.

Danaher’s expertise in areas such as biologics, or medicines made using living cells or organisms, puts it at the cutting edge of new treatments for diseases such as cancer and autoimmune deficiencies. Growth should also benefit from rising demand for rapid diagnostics.

It’s not all plain sailing. Many smaller biotechs have been caught up in a funding crunch for the past two years and the group has lost orders as a result. The good news is that Danaher said earlier this month it had noticed an improvement, though this has yet to translate into an increase in orders.

Revenues also fell last year, and will again this year, as the effects of a Covid-related sales boost fade and customers finish running down excess stock.

Danaher is confident the lull will be short-lived and is sticking with its central growth targets. The wider market also appears optimistic based on the punchy rating attached to the shares of 32 times forecast earnings. That’s a price several of the world’s best professional investors think is worth paying. This column agrees.

Questor says: buy

Ticker: NYSE:DHR

Share price: $253.38

Read the latest Questor column on telegraph.co.uk every Sunday, Tuesday, Wednesday, Thursday and Friday from 5am.

Read Questor’s rules of investment before you follow our tips.
Posted at 11/5/2024 08:22 by adw198
@hoohah In November they guided the market they expected to triple revenue to £6m. Based on that massive growth projection they forecast cash lasting till Q2 25.
Some of us are concerned whether we’re on track to achieve £6m because there’s no evidence to suggest that. We’ve had a $250k deal, a £150k deal and the £500k deal with AZ that complete Q1 25. Fair enough we don’t what else is being achieved that they haven’t announced and that’s particularly true of product sales but at the very least it’s a risk. If they aren’t on track and need to guide the market the results will be the time to do it. Those results are strangely later than previous which might suggest a placing will be announced around the same time. A placing isn’t the end of the world and I personally will almost certainly buy back in after it arrives because for me it de risks the prospects here. But it would most likely lead to a drop in the share price


Bones knows this very well because it’s the kind of analysis he applies to some of the many other message boards he slates other shares on. He just happens to want to pump the price here which is why he’s so aggressive to anyone who doesn’t play along with his agenda. What he’s admitted is he sold in January the exact time he was posting regularly about how great things were. Yet he’s also announced he hasn’t sold a penny.

Even if the above results / placing does play out it’s also possible there could be a stonking deal announced any time to send the share price much higher. That’s fine with me, we also have to make our own decisions and live with the consequences. I watched RENE go to nothing from a similar position so just want to manage my risk. Results will be in the next 2 weeks so the good news is we’ll be finding out very soon.
Posted at 05/5/2024 11:07 by purchaseatthetop
“Maybe theybarneworried they are going to miss out and are trying to get on board at a lower entry price. Good luck with that next week lol”

The reality is that nothing we post here has any impact on the share price. This is a place for discussion good or bad. The share price could certainly rise Monday but that will suit traders. The uplift would only be sustained with series of good news with numbers.
Posted at 05/5/2024 10:59 by bones698
It's. Funny how posters from the past appear and talk it down when good news arrives and the share price strarts to move. Coincidence. The same few that have sold out in the past come back and try to get the share price down talking rubbish and spammming th thread constantly.

Maybe theybarneworried they are going to miss out and are trying to get on board at a lower entry price. Good luck with that next week lol
Posted at 04/5/2024 16:05 by bones698
Adw that's a fair post I get your concerns and have long held those fears with AGL.
The thing is with a potential profits warning you elude to it would have come by now as berenberg forced them to issues them at the soonest possible oppurtunity in the past and the numbers with the 3 deals and kit sales etc look to be well. On track to deliver the revenue target.

There is nothing in the price at these levels for the potential future earnings here especially when you consider how far they have come with products and contracts with big companies.

They have restated q2 2025 several times now for cash runway, they are confident that is the case and even beyond depending on progress this year. I agree they will likely raise very late on this year or early next year but by then the share price will be higher given the news that is still to come from prostate and ovarian, thermo Fisher trial, talks with 11 other companies etc

I think you got this call wrong but each to their own, If you dont like the risk sell that's fair enough. I just think at these levels there is a lot of bad news priced in given the progress made and as you know I have always been one of the most pessimistic when it comes to agl over the years.

Gl whatever you decide to do I don't see many other companies in the position of agl out there with less risk and such potential that is now starting to deliver.
Angle share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock